EMA/PE/0000235869
Submitted by Anonymous (not verified) on 8 July 2026 - 8:30
EMA/PE/0000235869
EMA/PE/0000239491
Submitted by Anonymous (not verified) on 8 July 2026 - 8:27
EMA/PE/0000239491
EMA/PE/0000222352
Submitted by Anonymous (not verified) on 8 July 2026 - 8:24
EMA/PE/0000222352
EMA/PE/0000240548
Submitted by Anonymous (not verified) on 8 July 2026 - 8:19
EMA/PE/0000240548
Download website data in JSON data format
Submitted by Anonymous (not verified) on 7 July 2026 - 16:53
Download website data in JSON data format
Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 15, Status: Authorised
Submitted by Anonymous (not verified) on 7 July 2026 - 16:18
Human medicines European public assessment report (EPAR): Sarclisa, isatuximab, Date of authorisation: 30/05/2020, Revision: 15, Status: Authorised
List of medicines currently in PRIME scheme
Submitted by Anonymous (not verified) on 7 July 2026 - 16:00
List of medicines currently in PRIME scheme
Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Date of authorisation: 21/04/2021, Revision: 14, Status: Authorised
Submitted by Anonymous (not verified) on 7 July 2026 - 15:40
Human medicines European public assessment report (EPAR): Abevmy, bevacizumab, Date of authorisation: 21/04/2021, Revision: 14, Status: Authorised
EMA/PE/0000241119
Submitted by Anonymous (not verified) on 7 July 2026 - 15:02
EMA/PE/0000241119
EMA/PE/0000239082
Submitted by Anonymous (not verified) on 7 July 2026 - 14:59
EMA/PE/0000239082